Ghassan K. Abou-Alfa, MD

Articles

Dr. Abou-Alfa on Remaining Questions With Infigratinib in FGFR2+ Cholangiocarcinoma

July 16th 2020

Ghassan K. Abou-Alfa, MD, discusses the questions that remain with infigratinib in advanced cholangiocarcinoma with FGFR2 gene fusions/translocations.

Dr. Abou-Alfa on Sequencing Challenges in Metastatic HCC

April 11th 2020

Ghassan K. Abou-Alfa, MD, discusses sequencing challenges in metastatic hepatocellular carcinoma.

Dr. Abou-Alfa on Optimizing Treatment Selection in HCC

February 29th 2020

Ghassan K. Abou-Alfa, MD, discusses ways to optimize treatment selection for patients with hepatocellular carcinoma.

Dr. Abou-Alfa on Progress Made in Hepatocellular Carcinoma

February 11th 2020

Ghassan K. Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the progress that has been made in the treatment of patients with hepatocellular carcinoma (HCC).

Dr. Abou-Alfa on Ramucirumab as Second-Line Therapy for Hepatocellular Carcinoma

January 23rd 2020

Ghassan K. Abou-Alfa, MD, discusses the role of ramucirumab in the treatment of patients with hepatocellular carcinoma in the second-line setting.

Dr. Abou-Alfa on the Results of the ClarIDHy Trial in Advanced Cholangiocarcinoma

November 1st 2019

Ghassan K. Abou-Alfa, MD, discusses the results of the phase III ClarIDHy trial in advanced cholangiocarcinoma.

Dr. Abou-Alfa on the FDA Approval of Cabozantinib in HCC

January 20th 2019

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the FDA approval of cabozantinib (Cabometyx) is likely to shake up the landscape and impact sequencing for patients with hepatocellular carcinoma (HCC).

Dr. Abou-Alfa on Key Trends in HCC Research

September 15th 2018

Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, describes what he sees as key areas of research into the treatment of hepatocellular carcinoma as therapy moves beyond existing drugs and into novel approaches.

Dr. Abou-Alfa on Sequencing Agents in the Treatment of Patients With HCC

February 3rd 2018

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the potential approval of cabozantinib (Cabometyx) in hepatocellular carcinoma (HCC) could affect the treatment landscape in liver cancer.

Dr. Abou-Alfa Discusses Results of the CELESTIAL Trial in Advanced HCC

January 21st 2018

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the CELESTIAL trial in advanced hepatocellular carcinoma during the 2018 Gastrointestinal Cancers Symposium.

Dr. Abou-Alfa Discusses Treatment Options in Liver Cancer

January 17th 2018

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options in liver cancer.

Dr. Abou-Alfa on Checkpoint Inhibitors in Liver Cancer

January 3rd 2018

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses checkpoint inhibitors in liver cancer.

Dr. Abou-Alfa on the Ongoing Impact and Role of Regorafenib in HCC

November 9th 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ongoing role and impact of regorafenib (Stivarga) in the paradigm of hepatocellular carcinoma (HCC) in an interview during the 2017 Chemotherapy Foundation Symposium.

Dr. Abou-Alfa on Trials Investigating Immunotherapy in HCC

June 22nd 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses trials investigating immunotherapy in hepatocellular carcinoma (HCC).

Dr. Abou-Alfa on the Role of Immunotherapy in HCC

May 6th 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy for patients with hepatocellular carcinoma (HCC).

Dr. Abou-Alfa on Trial of MEK162 in Advanced Biliary Cancer

April 3rd 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the trial of MEK162 in combination with gemcitabine and cisplatin in patients with untreated advanced biliary cancer.

Dr. Abou-Alfa Discusses Ongoing Studies of Immunotherapy in HCC

January 22nd 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing studies investigating immunotherapy in hepatocellular carcinoma.

Dr. Ghassan Abou-Alfa on Impact of Second-Line Regorafenib in HCC

November 17th 2016

​Ghassan K. Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the impact of the phase III RESORCE trial, which demonstrated that regorafenib improved survival over placebo for patients with hepatocellular carcinoma (HCC) that progressed on sorafenib.

Dr. Abou-Alfa on Significance of RESORCE Trial for HCC

July 26th 2016

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the significance of the RESORCE trial, which explored regorafenib (Stivarga) versus best supportive care for patients with unresectable hepatocellular carcinoma who progressed after receiving sorafenib (Nexavar).

Dr. Abou-Alfa on Sorafenib Plus Doxorubicin in Patients With HCC

January 22nd 2016

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the CALGB 80802 study, which examined sorafenib versus sorafenib plus doxorubicin in patients with advanced hepatocellular carcinoma in the first-line setting.